

Merck's commitment to American manufacturing, R&D and economic growth

For more than 130 years, Merck, a leading American biopharmaceutical company, has been committed to saving and improving lives by developing and delivering life-changing medicines and vaccines to treat diseases in both humans and animals.

Headquartered in the United States, we remain committed to continuously bolstering the American economy and enhancing the communities where we operate through substantial investments in innovation in U.S. manufacturing and research and development (R&D).



Since the enactment of the 2017 tax reform law, we have allocated more than **\$12 billion** in capital expenses to enhance American manufacturing and R&D capabilities with plans to invest more than **\$9 billion** over the next four years. As part of this, our company recently expanded our Durham, North Carolina plant with a **\$1 billion** investment and broke ground on a **\$1 billion** state-of-the-art facility in Delaware.

We have also invested more than **\$81 billion** in U.S.-related R&D since 2018.

Additionally, we will continue relocating several manufacturing operations and jobs from overseas to the U.S., including production of KEYTRUDA in 2026 with the intent of having KEYTRUDA for American patients made in America. We also boast a U.S.-based Animal Health network of sites where we manufacture a broad portfolio of vaccines and large molecule therapies made end to end in the U.S.

All these efforts to stimulate American economic growth allow for the domestic production and distribution of U.S. medicines and vaccines to protect patients while generating:

More than

7,500

full-time U.S.-based high-paying, meaningful employment opportunities — *an increase of nearly 26% since 2018 as a result of the tax reform law*

Upwards of

48,000

construction opportunities, with more than 37,600 forecast for 2025-2028

An average of

1,600

contract positions per year since 2019

Furthermore, we plan to invest **\$3.5 billion** in biologics and small molecule manufacturing sites/capabilities in the U.S., expected to create more than **650 jobs**, while also investing **\$3.5+ billion** in our Rahway headquarters, which will create roughly **1,000 jobs** across research and clinical manufacturing.



Updated Q2 2025

U.S. manufacturing by the numbers

In 2026, we plan to bring **KEYTRUDA** manufacturing operations for U.S. patients to the U.S.

Our upcoming launch of **clesrovimab (MK-1654)**, is a 100% U.S. supply chain.

We are the sole supplier of **TICE BCG**.

U.S. FINISHED GOODS

More than

94%

of Merck's U.S. saleable units are packaged at facilities in North Carolina and Pennsylvania, with additional support from U.S. contract manufacturers.

VACCINE MANUFACTURING

Over

85%

of vaccine drug substances are produced in the U.S. for both domestic and global markets, reflecting our strong domestic manufacturing focus.

VACCINE FORMULATION AND PACKAGING

More than

98%

of vaccine formulation, filling or packaging for the U.S. market occurs at domestic sites, with about **50%** of international demand also fulfilled from U.S. facilities.

Key Investments

DURHAM, NORTH CAROLINA (MARCH 2025)

\$1 billion

investment generating nearly **400** full-time jobs and roughly **4,000** construction jobs

WILMINGTON, DELAWARE (APRIL 2025)

A more than

\$1 billion

investment in a **470,000 sq. ft.** biologics commercialization and launch facility generating approximately **500** full-time jobs and roughly **4,000** construction jobs

Potential further expansion of the site would create an additional **1,500** full-time roles and **26,000** construction jobs

Future manufacturing site for KEYTRUDA for U.S. patients

Significant investment

Bringing the manufacturing of KEYTRUDA to Delaware marks an unparalleled investment.

Patient impact

Manufacturing in the U.S. brings the immunotherapy closer to the American patients who rely on KEYTRUDA.

Strong U.S. footprint

By producing KEYTRUDA in the U.S., as well as numerous future biologic products, we are reaffirming our commitment to a strong U.S. footprint that supports the President's economic agenda.

Trusted partner

Merck is a constructive partner that is willing to participate in the policy and pressing conversations that have significant implications for our operating environment.



Impact

U.S. CAPITAL INVESTMENTS

Invested more than

\$12 billion

in U.S. capital, dedicated to expanding American manufacturing and R&D capabilities, and plans to invest more than **\$9 billion** over the next four years.

OVERALL JOB CREATION

Full-time:

Created over

7,500

U.S.-based, full-time jobs — *a nearly **26%** growth since 2018.*

Trade/ construction:

Hired more than

48,000

workers from 2018 - 2024; forecasting **more than 37,600** from 2025 - 2028.

Contract:

Averaged

1,600

contract positions per year over the past five years.

AVERAGE ANNUAL EARNINGS

Forecasting

\$1.4 billion

average annual earnings for U.S.-based manufacturing employees from 2025 - 2028.

State snapshot*

Merck continues to invest in manufacturing and R&D capabilities across the country. We are committed to creating more high-paying, meaningful job opportunities within the United States, ensuring domestic production and distribution of U.S. medicines and vaccines and supporting the communities where we operate through philanthropic contributions, job training programs and various partnerships.

Merck’s U.S. manufacturing headcount increased by 1,700 full-time employees between 2018 and 2024 driven by continued investment in our West Point, Pennsylvania, Elkton, Virginia, and Durham and Wilson, North Carolina sites primarily in the vaccines space. Continued investment in these sites, as well as new sites for biologics in Delaware (500 employees and a potential 1,500 more) and for small molecules in a U.S. location yet to be identified (nearly 200 full time employees), will drive incremental job creation. Offsetting these potential future increases are previously announced actions at Riverside, Pennsylvania, Elkton, Virginia (antibiotics only) and Las Piedras, Puerto Rico.

California

TOTAL IN STATE	SOUTH SAN FRANCISCO	SAN DIEGO	PALO ALTO
Invested \$236M+ (2018-2024) and expecting \$19M+ (2025-2028)	Invested \$230M+ (2018-2024) and expecting \$17M+ (2025-2028)	Invested \$3M+ (2018-2024) and expecting \$2M+ (2025-2028)	Invested \$3M+ (2018-2024)

512
jobs created across
the state (2018-2025)



Delaware

TOTAL IN STATE

Invested
\$256M+
(2018-2024)
and expecting
\$1B+ (2025-2028)

82
jobs created across
the state (2018-2025)

MILLSBORO

Invested
\$207M+
(2018-2024)
and expecting
\$105M+ (2025-2028)

WILMINGTON

Invested
\$49M
(2018-2024)
and expecting
\$1B+ (2025-2028)

Iowa

AMES/ TOTAL IN STATE

Invested
\$7M+
(2018-2024)
and expecting
\$2M+ (2025-2028)

6
jobs created across
the state (2018-2025)

Kansas

DESOTO/ TOTAL IN STATE

Invested
\$242M+
(2018-2024)
and expecting
\$242M+ (2025-2028)

136
jobs created across
the state (2018-2025)

Louisiana

BATON ROUGE/ TOTAL IN STATE

Invested
\$2M+
(2018-2024)
and expecting
\$2M+ (2025-2028)

Massachusetts

TOTAL IN STATE	BOSTON	CAMBRIDGE	WATERTOWN
Invested \$169M+ (2018-2024) and expecting \$18M+ (2025-2028)	Invested \$89M+ (2018-2024) and expecting \$11M+ (2025-2028)	Invested \$80M+ (2018-2024) and expecting \$6M+ (2025-2028)	Invested \$34K+ (2018-2024)
278 jobs created across the state (2018-2025)			

MinnesotaNebraska

WORTHINGTON/ TOTAL IN STATE	ELKHORN/ TOTAL IN STATE
Invested \$18M+ (2018-2024) and expecting \$30M+ (2025-2028)	Invested \$408M+ (2018-2024) and expecting \$355M+ (2025-2028)
10 jobs created across the state (2018-2025)	124 jobs created across the state (2018-2025)

New Jersey

TOTAL IN STATE	RAHWAY	KENILWORTH	MADISON
Invested \$2.9B+ (2018-2024) and expecting \$3.5B+ (2025-2028)	Invested \$2.7B+ (2018-2024) and expecting \$3.5B+ (2025-2028)	Invested \$129M (2018-2024)	Invested \$25M+ (2018-2024) and expecting \$541K (2025-2028)
3,642 jobs created across the state (2018-2025)			
WHITEHOUSE	BRANCHBURG		
Invested \$20M+ (2018-2024) and expecting \$4M+ (2025-2028)	Invested \$2M+ (2018-2024)		

North Carolina

TOTAL IN STATE	DURHAM	WILSON	CHARLOTTE
Invested \$2.18B+ (2018-2024) and expecting \$390M+ (2025-2028)	Invested \$1.85B+ (2018-2024) and expecting \$265M+ (2025-2028)	Invested \$316M+ (2018-2024) and expecting \$124M+ (2025-2028)	Invested \$9M+ (2018-2024) and expecting \$1M+ (2025-2028)
513 jobs created across the state (2018-2025)			



Pennsylvania

TOTAL IN STATE	WEST POINT	NORTH WALES	UPPER GWYNEDD
Invested \$4.17B+ (2018-2024) and expecting \$2.7B+ (2025-2028)	Invested \$3.87B+ (2018-2024) and expecting \$2.4B+ (2025-2028)	Invested \$95M+ (2018-2024) and expecting \$153M+ (2025-2028)	Invested \$84M+ (2018-2024) and expecting \$121M+ (2025-2028)
2,169 jobs created across the state (2018-2025)			
RIVERSIDE	SPRINGHOUSE		
Invested \$64M+ (2018-2024)	Invested \$55M+ (2018-2024)		

Virginia

ELKTON/ TOTAL IN STATE
Invested \$1.48B+ (2018-2024) and expecting \$257M+ (2025-2028)
309 jobs created across the state (2018-2025)



*State job information represents U.S. -based full-time employees at all U.S. Merck locations.